ELVN-002 is under clinical development by Enliven Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ELVN-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ELVN-002 overview

ELVN-002 is under development for the treatment of solid tumors including non-small cell lung cancer, HER2 positive breast cancer, gastric cancer and colorectal cancer. It acts by targeting human epidermal growth factor receptor 2 (HER2), and key mutations of HER2. It is administered through oral route.

Enliven Therapeutics overview

Enliven Therapeutics, formerly a Imara, is a clinical-stage precision oncology company that discovers and develops small molecule kinase inhibitors. The company product pipeline includes ELVN- 001 and ELVN- 002. Its product treats chronic myeloid leukemia (CML), non-small cell lung cancer (NSCLC) and solid tumors. Enliven Therapeutics pipeline program includes BCR-ABL and HER2 which carries out gene fusion, oncogenic, small molecule inhibitors and HER2 mutations including exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). The company includes ABL 1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Enliven Therapeutics is headquartered in Boulder, Colorado, the US.

For a complete picture of ELVN-002’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.